No Data
No Data
QIAGEN, Lilly to Develop Alzheimer's Risk Detection Test
Eli Lilly Alzheimer's Drug Set to Face Same Fate as Biogen's in U.K.: Report
Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
Biogen, Eisai New Alzheimer's Drug Considered Too Costly in Britain
The Alzheimer's disease drug Leqembi, owned by Biogen (BIIB.US) and Esai (ESALF.US), has been approved for sale in the United Kingdom.
According to the Sina Finance app, Biogen (BIIB.US) and its Japanese partner Eisai (ESALF.US) announced on Thursday that their groundbreaking Alzheimer's treatment drug, Leqembi (lecanemab), has been granted marketing authorization in the United Kingdom.
Bernstein Initiates EISAI CO LTD(ESALF.US) With Buy Rating, Announces Target Price $65.97
Bernstein analyst Miki Sogi initiates coverage on $EISAI CO LTD(ESALF.US)$ with a buy rating, and sets the target price at $65.02.According to TipRanks data, the analyst has a success rate of 0.0%
No Data